Measuring respiratory symptoms of COPD: Performance of the EXACT- Respiratory Symptoms Tool (E-RS) in three clinical trials

Respiratory Research

Volumn 15, Issue 1, 2014, Pages

  Leidy, Nancy K ^a   Murray, Lindsey T ^a   Monz, Brigitta U ^b   Nelsen, Linda ^c   Goldman, Mitchell ^d   Jones, Paul W ^e   Dansie, Elizabeth J ^a   Sethi, Sanjay ^f  

^a EVIDERA   (United States)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c MERCK RESEARCH LABORATORIES   (United States)

^d ASTRAZENECA   (United Kingdom)

^e ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^f UNIVERSITY AT BUFFALO   (United States)

Author keywords

Chest symptoms; Clinical trials; COPD; Cough; Dyspnoea; Respiratory symptoms; Sputum

Indexed keywords

ALVELESTAT; BUDESONIDE PLUS FORMOTEROL; LEVOFLOXACIN; TIOTROPIUM BROMIDE;

6 MINUTE WALK DISTANCE TEST; ADULT; ARTICLE; BREATHLESSNESS, COUGH, AND SPUTUM SCALE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; COUGHING; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DYSPNEA; EXACT RESPIRATORY SYMPTOM TOOL; EXERCISE TOLERANCE; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; FUNCTIONAL PERFORMANCE INVENTORY SHORT FORM; HUMAN; INCREMENTAL SHUTTLE WALK TEST; INTERNAL CONSISTENCY; MAJOR CLINICAL STUDY; MALE; MODIFIED MEDICAL RESEARCH COUNCIL DYSPNEA SCALE; MULTICENTER STUDY; PERFORMANCE; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; RESPIRATORY TRACT DISEASE ASSESSMENT; SPIROMETRY; ST. GEORGE RESPIRATORY QUESTIONNAIRE; SYMPTOMATOLOGY; THORAX DISEASE; VALIDATION STUDY; AGED; CLINICAL TRIAL; COMPLICATION; COUGH; DISEASE COURSE; DRUG EFFECTS; EXERCISE TEST; HEALTH STATUS; LUNG; MIDDLE AGED; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL; PREDICTIVE VALUE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRE; SEVERITY OF ILLNESS INDEX; SPUTUM; TIME FACTOR; TREATMENT OUTCOME;

AGED; COUGH; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DYSPNEA; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; HEALTH STATUS; HUMANS; LUNG; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; SPUTUM; SURVEYS AND QUESTIONNAIRES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84978036879     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/s12931-014-0124-z     Document Type: Article

References (41)

1. Calverley PM, Georgopopoulos D: Chronic obstructive pulmonary disease: symptoms and signs. Eur Respir Mon. 2006, 38: 7-23.
2. Celli BR, MacNee W: Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004, 23: 932-946. 10.1183/09031936.04.00014304.
3. Chong-Chen LU: Bronchodilator therapy for chronic obstructive pulmonary disease. Respirology. 1997, 2: 317-322. 10.1111/j.1440-1843.1997.tb00096.x.
4. Draft guidance for industry on chronic obstructive pulmonary disease: developing drugs for treatment; availability. Fed Regist. 2007, 72: 63618-
5. Global Initiative for Chronic Obstructive Lung Disease: Global Strategy for the Diagnosis, Management, and Prevention of COPD. [], [ http://www.goldcopd.org/uploads/users/files/GOLD_Report_2014_Jan23.pdf ]
6. Siafakas NM, Celli B: Overall management of stable chronic obstructive pulmonary disease. Eur Respir Mon. 2006, 38: 258-265.
7. Viegi G, Pistelli F, Sherrill DL, Maio S, Baldacci S, Carrozzi L: Definition, epidemiology and natural history of COPD. Eur Respir J. 2007, 30: 993-1013. 10.1183/09031936.00082507.
8. Cooper CB: The connection between chronic obstructive pulmonary disease symptoms and hyperinflation and its impact on exercise and function. Am J Med. 2006, 119 (Suppl 1): 21-31. 10.1016/j.amjmed.2006.08.004.
9. Ries AL: Impact of chronic obstructive pulmonary disease on quality of life: the role of dyspnea. Am J Med. 2006, 119 (Suppl 1): 12-20. 10.1016/j.amjmed.2006.08.003.
10. Tsiligianni I, Kocks J, Tzanakis N, Siafakas N, van der Molen T: Factors that influence disease-specific quality of life or health status in patients with COPD: a review and meta-analysis of Pearson correlations. Prim Care Respir J. 2011, 20: 257-268. 10.4104/pcrj.2011.00029.
11. Leidy NK, Wilcox TK, Jones PW, Murray L, Winnette R, Howard K, Petrillo J, Powers J, Sethi S: Development of the EXAcerbations of Chronic Obstructive Pulmonary Disease Tool (EXACT): a patient-reported outcome (PRO) measure. Value Health. 2010, 13: 965-975. 10.1111/j.1524-4733.2010.00772.x.
12. Jones PW, Chen WH, Wilcox TK, Sethi S, Leidy NK: Characterizing and quantifying the symptomatic features of COPD exacerbations. Chest. 2011, 139: 1388-1394. 10.1378/chest.10-1240.
13. Leidy NK, Wilcox TK, Jones PW, Roberts L, Powers JH, Sethi S: Standardizing measurement of chronic obstructive pulmonary disease exacerbations. Reliability and validity of a patient-reported diary. Am J Respir Crit Care Med. 2011, 183: 323-329. 10.1164/rccm.201005-0762OC.
14. Leidy NK, Murray LT, Jones P, Sethi S: Performance of the EXAcerbations of chronic pulmonary disease tool patient-reported outcome measure in three clinical trials of chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2014, 11: 316-325. 10.1513/AnnalsATS.201309-305OC.
15. Leidy NK, Murray LT: Patient-reported outcome (PRO) measures for clinical trials of COPD: the EXACT and E-RS. COPD. 2013, 10: 393-398. 10.3109/15412555.2013.795423.
16. Draft guidance for industry on qualification of exacerbations of chronic pulmonary disease tool for measurement of symptoms of acute bacterial exacerbations of chronic bronchitis in patients with chronic obstructive pulmonary disease. Fed Regist. 2014, 79: 1873-1874.
17. Guidance for industry on patient-reported outcome measures: use in medical product development to support labeling claims. Fed Regist. 2009, 74: 65132-65133.
18. Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, Ring L: Content validity-establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1-eliciting concepts for a new PRO instrument. Value Health. 2011, 14: 967-977. 10.1016/j.jval.2011.06.014.
19. Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, Ring L: Content validity-establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2-assessing respondent understanding. Value Health. 2011, 14: 978-988. 10.1016/j.jval.2011.06.013.
20. Leidy NK, Sexton CC, Jones PW, Notte SM, Monz BU, Nelsen L, Goldman M, Murray LT, Sethi S: Measuring respiratory symptoms in clinical trials of COPD: reliability and validity of a daily diary. Thorax. 2014, 69: 424-430. 10.1136/thoraxjnl-2013-204428.
21. Vogelmeier C, Aquino TO, O'Brien CD, Perrett J, Gunawardena KA: A randomised, placebo-controlled, dose-finding study of AZD9668, an oral inhibitor of neutrophil elastase, in patients with chronic obstructive pulmonary disease treated with tiotropium. COPD. 2012, 9: 111-120. 10.3109/15412555.2011.641803.
22. Kuna P, Jenkins M, O'Brien CD, Fahy WA: AZD9668, a neutrophil elastase inhibitor, plus ongoing budesonide/formoterol in patients with COPD. Respir Med. 2012, 106: 531-539. 10.1016/j.rmed.2011.10.020.
23. Leidy NK, Schmier JK, Jones MK, Lloyd J, Rocchiccioli K: Evaluating symptoms in chronic obstructive pulmonary disease: validation of the Breathlessness, Cough and Sputum Scale. Respir Med. 2003, 97 (Suppl A): S59-S70. 10.1016/S0954-6111(03)80016-1.
24. Leidy NK, Rennard SI, Schmier J, Jones MK, Goldman M: The breathlessness, cough, and sputum scale: the development of empirically based guidelines for interpretation. Chest. 2003, 124: 2182-2191. 10.1378/chest.124.6.2182.
25. Jones PW, Quirk FH, Baveystock CM, Littlejohns P: A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis. 1992, 145: 1321-1327. 10.1164/ajrccm/145.6.1321.
26. Fletcher CM, Elmes PC, Fairbairn AS, Wood CH: The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. Br Med J. 1959, 2: 257-266. 10.1136/bmj.2.5147.257.
27. Leidy NK, Knebel A: Clinical validation of the Functional Performance Inventory in patients with COPD. Respir Care. 1999, 44: 932-939.
28. Leidy NK, Hamilton A, Becker K: Assessing patient report of function: content validity of the Functional Performance Inventory-Short Form (FPI-SF) in patients with chronic obstructive pulmonary disease (COPD). Int J Chron Obstruct Pulmon Dis. 2012, 7: 543-554. 10.2147/COPD.S32032.
29. Jones PW: St. George's Respiratory Questionnaire: MCID. COPD. 2005, 2: 75-79. 10.1081/COPD-200050513.
30. Puhan MA, Chandra D, Mosenifar Z, Ries A, Make B, Hansel NN, Wise RA, Sciurba F: The minimal important difference of exercise tests in severe COPD. Eur Respir J. 2011, 37: 784-790. 10.1183/09031936.00063810.
31. Singh SJ, Jones PW, Evans R, Morgan MD: Minimum clinically important improvement for the incremental shuttle walking test. Thorax. 2008, 63: 775-777. 10.1136/thx.2007.081208.
32. Hays RD, Anderson RT, Revicki DA: Assessing reliability and validity of measurement in clinical trials. Quality of Life Assessment in Clinical Trials: Methods and Practice. Edited by: Staquet MJ, Hays RD. 1998, Oxford University Press, New York, 169-182.
33. Nunnally JC, Bernstein IH: Psychometric Theory. 1994, McGraw-Hill, New York
34. Chinn S: Statistics in respiratory medicine. 2. Repeatability and method comparison. Thorax. 1991, 46: 454-456. 10.1136/thx.46.6.454.
35. Assessing Quality of Life in Clinical Trials: Methods and Practice. 2005, Oxford University Press, New York
36. Rutten-van Molken M, Roos B, Van Noord JA: An empirical comparison of the St George's Respiratory Questionnaire (SGRQ) and the Chronic Respiratory Disease Questionnaire (CRQ) in a clinical trial setting. Thorax. 1999, 54: 995-1003. 10.1136/thx.54.11.995.
37. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N: Development and first validation of the COPD Assessment Test. Eur Respir J. 2009, 34: 648-654. 10.1183/09031936.00102509.
38. Gupta N, Pinto LM, Morogan A, Bourbeau J: The COPD assessment test: a systematic review.Eur Respir J 2014. in press.,
39. Johnston N, O'Byrne P, Kolb M: The promise of electronic data capture in respiratory medicine. Eur Respir J. 2011, 37: 228-230. 10.1183/09031936.00141310.
40. Jones PW, Beeh KM, Chapman KR, Decramer M, Mahler DA, Wedzicha JA: Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med. 2014, 189 (3): 250-255. 10.1164/rccm.201310-1863PP.
41. Beier J, Kirsten AM, Mroz R, Segarra R, Chuecos F, Caracta C, Gil EG: Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study. COPD. 2013, 10: 511-522. 10.3109/15412555.2013.814626.